FIG 9.

In vivo antiviral activity of salinomycin in combination with OSV-P against rgK/09Δ(H275Y). The experimental scheme was identical with that of Fig. 8, with minor modifications of OSV-P doses. Groups of five mice were challenged with 5 MLD₅₀ of the mouse-adapted OSV-resistant 2009 pandemic strain and treated with OSV-P (10 mg/kg or 100 mg/kg) alone or in the presence of salinomycin (10 mg/kg). Body weight changes (A) and mortality (B) were monitored from days 0 to 14. Statistical analysis was performed using two-tailed Student’s t test relative to the OSV-P (100 mg/kg) group. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.